Moderna Inc (MRNA)vsNuvation Bio Inc (NUVB)
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
NUVB
Nuvation Bio Inc
$4.59
+0.88%
HEALTHCARE · Cap: $1.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 1211% more annual revenue ($2.23B vs $169.90M). NUVB leads profitability with a -88.2% profit margin vs -141.4%. NUVB earns a higher WallStSmart Score of 27/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NUVB
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Intrinsic value data unavailable for NUVB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Revenue surging 556.0% year-over-year
Areas to Watch
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -45.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NUVB
The strongest argument for NUVB centers on Revenue Growth. Revenue growth of 556.0% demonstrates continued momentum.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NUVB
The primary concerns for NUVB are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NUVB is a hypergrowth play — different risk/reward profiles.
NUVB carries more volatility with a beta of 1.62 — expect wider price swings.
NUVB is growing revenue faster at 556.0% — sustainability is the question.
NUVB generates stronger free cash flow (-43M), providing more financial flexibility.
Bottom Line
NUVB scores higher overall (27/100 vs 21/100) and 556.0% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Nuvation Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?